NCT02014844

Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma

An Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of Aldoxorubicin in Subjects With Unresectable Glioblastoma Whose Tumors Have Progressed Following Prior Treatment With Surgery, Radiation and Temozolomide

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: ImmunityBio, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a pilot study to determine the efficacy and safety of aldoxorubicin in subjects with glioblastoma who have progressed following surgery and prior treatments.

Detailed description

This is a second line open-labeled pilot phase 2 study in subjects with glioblastoma whose tumors have progressed following prior treatment with surgery, radiation and Temozolomide. Patients who have received avastin as a second-line treatment are not eligible for this study.

Conditions

• Glioblastoma

Interventions

Type	Name	Description
DRUG	250 mg/m2 aldoxorubicin
DRUG	350 mg/m2 aldoxorubicin

Timeline

• Start date: 2014-03-01
• Primary completion: 2016-12-01
• Completion: 2016-12-01
• First posted: 2013-12-18
• Last updated: 2024-05-29
• Results posted: 2024-05-29

Locations

4 sites across 1 country: United States